Abstract: The invention relates to an isolated nucleic acid molecule comprising a nucleic acid sequence encoding a protein having the amino acid sequence as depicted in SEQ ID NO:10, and sequences having at least 70% sequence identity with said amino acid sequence and conferring self-compatibility to a potato plant. The invention further relates to a transformed plant that comprises the nucleic acid sequence, and parts thereof. The invention further related to methods for the selection and methods for the production of a plant comprising the nucleic acid sequence, and to a plant that is obtainable by these methods. Said plant may further comprise at least one allele of each of a Phytophtera infestance resistance gene selected from S. avilesii 478-2 Rpi*-avl1, S. tarinjense 852-5 Rpi-tar1, S. chacoense 543-5 Rpi-chc1, and S. venturii 283-1 Rpi-vnt1. The invention further relates to a food product that is prepared from a part of a plant part of the invention.

Abstract: Processes for the production of large quantities of diploid F1 Solanum potato tubers that are uniform in shape are provided. Diploid F1 hybrid plants are produced from true seeds. The tubers produced by the diploid F1 hybrid plants are either harvested for consumption, processing or extraction, or for production of seedling tubers which are then planted to produce tubers for consumption, processing or extraction. Also provided are diploid F1 hybrid seeds and plants that produce large quantities of tubers that are uniform in shape and produce large quantities of sprouts per tuber when used as seedling tubers.

Abstract: The present invention relates to a diploid, fertile, self-compatible and highly homozygous tuber-bearing Solanum species potato line designated Solyntus. The potato line Solyntus produces 15 to 20 tubers per plant. The tubers have a yellow flesh. The phenotype of the plant and tuber is stable through both sexual and asexual reproduction. The potato line Solyntus is produced from seeds or by asexual reproduction of tubers or other plant parts.

Abstract: The present disclosure provides engineered ketoreductase enzymes having improved properties as compared to a naturally occurring wild-type ketoreductase enzyme including the capability of reducing 5-((4S)-2-oxo-4-phenyl(1,3-oxazolidin-3-yl))-1-(4-fluorophenyl)pentane-1,5-dione to (4S)-3-[(5S)-5-(4-fluorophenyl)-5-hydroxypentanoyl]-4-phenyl-1,3-oxazolidin-2-one. Also provided are polynucleotides encoding the engineered ketoreductase enzymes, host cells capable of expressing the engineered ketoreductase enzymes, and methods of using the engineered ketoreductase enzymes to synthesize the intermediate (4S)-3-[(5S)-5-(4-fluorophenyl)-5-hydroxypentanoyl]-4-phenyl-1,3-oxazolidin-2-one in a process for making Ezetimibe.

Abstract: The present disclosure provides engineered halohydrin dehalogenase (HHDH) polypeptides having improved enzyme properties as compared to the wild-type HHDH enzyme HheC and other reference engineered HHDH polypeptides. Also provided are polynucleotides encoding the engineered HHDH enzymes, host cells capable of expressing the engineered HHDH enzymes, and methods of using the engineered HHDH enzymes to synthesize a variety of chiral compounds including chiral epoxides and chiral alcohols.

Abstract: The present disclosure provides engineered ketoreductase enzymes having improved properties as compared to a naturally occurring wild-type ketoreductase enzyme including the capability of reducing 5-((4S)-2-oxo-4-phenyl(1,3-oxazolidin-3-yl))-1-(4-fluorophenyl)pentane-1,5-dione to (4S)-3-[(5S)-5-(4-fluorophenyl)-5-hydroxypentanoyl]-4-phenyl-1,3-oxazolidin-2-one. Also provided are polynucleotides encoding the engineered ketoreductase enzymes, host cells capable of expressing the engineered ketoreductase enzymes, and methods of using the engineered ketoreductase enzymes to synthesize the intermediate (4S)-3-[(5S)-5-(4-fluorophenyl)-5-hydroxypentanoyl]-4-phenyl-1,3-oxazolidin-2-one in a process for making Ezetimibe.

Abstract: The present disclosure provides engineered ketoreductase enzymes having improved properties as compared to a naturally occurring wild-type ketoreductase enzyme including the capability of reducing 5-((4S)-2-oxo-4-phenyl(1,3-oxazolidin-3-yl))-1-(4-fluorophenyl)pentane-1,5-dione to (4S)-3-[(5S)-5-(4-fluorophenyl)-5-hydroxypentanoyl]-4-phenyl-1,3-oxazolidin-2-one. Also provided are polynucleotides encoding the engineered ketoreductase enzymes, host cells capable of expressing the engineered ketoreductase enzymes, and methods of using the engineered ketoreductase enzymes to synthesize the intermediate (4S)-3-[(5S)-5-(4-fluorophenyl)-5-hydroxypentanoyl]-4-phenyl-1,3-oxazolidin-2-one in a process for making Ezetimibe.

Abstract: The present disclosure provides engineered ketoreductase enzymes having improved properties as compared to a naturally occurring wild-type ketoreductase enzyme including the capability of reducing 5-((4S)-2-oxo-4-phenyl(1,3-oxazolidin-3-yl))-1-(4-fluorophenyl)pentane-1,5-dione to (4S)-3-[(5S)-5-(4-fluorophenyl)-5-hydroxypentanoyl]-4-phenyl-1,3-oxazolidin-2-one. Also provided are polynucleotides encoding the engineered ketoreductase enzymes, host cells capable of expressing the engineered ketoreductase enzymes, and methods of using the engineered ketoreductase enzymes to synthesize the intermediate (4S)-3-[(5S)-5-(4-fluorophenyl)-5-hydroxypentanoyl]-4-phenyl-1,3-oxazolidin-2-one in a process for making Ezetimibe.

Abstract: The present disclosure provides engineered halohydrin dehalogenase (HHDH) polypeptides having improved enzyme properties as compared to the wild-type HHDH enzyme HheC and other reference engineered HHDH polypeptides. Also provided are polynucleotides encoding the engineered HHDH enzymes, host cells capable of expressing the engineered HHDH enzymes, and methods of using the engineered HHDH enzymes to synthesize a variety of chiral compounds including chiral epoxides and chiral alcohols.

Abstract: The present disclosure provides engineered halohydrin dehalogenase (HHDH) polypeptides having improved enzyme properties as compared to the wild-type HHDH enzyme HheC and other reference engineered HHDH polypeptides. Also provided are polynucleotides encoding the engineered HHDH enzymes, host cells capable of expressing the engineered HHDH enzymes, and methods of using the engineered HHDH enzymes to synthesize a variety of chiral compounds including chiral epoxides and chiral alcohols.

Abstract: The invention relates to a Piroplasmid protein or an immunogenic fragment of the protein, and to a nucleic acid encoding the Piroplasmid protein or immunogenic fragment. Furthermore, the invention relates to cDNA fragments, recombinant DNA molecules and live recombinant carriers comprising the nucleic acid. Also the invention relates to host cells comprising the cDNA fragments, recombinant DNA molecules and live recombinant carriers. Finally, the invention relates to vaccines comprising a Piroplasmid protein or an immunogenic fragment of the protein, to methods for the preparation of such vaccines, to the use of such proteins or fragments for vaccine purposes, and to diagnostic tests.

Abstract: The present disclosure provides engineered halohydrin dehalogenase (HHDH) polypeptides having improved enzyme properties as compared to the wild-type HHDH enzyme HheC and other reference engineered HHDH polypeptides. Also provided are polynucleotides encoding the engineered HHDH enzymes, host cells capable of expressing the engineered HHDH enzymes, and methods of using the engineered HHDH enzymes to synthesize a variety of chiral compounds including chiral epoxides and chiral alcohols.

Abstract: The present disclosure provides engineered ketoreductase enzymes having improved properties as compared to a naturally occurring wild-type ketoreductase enzyme including the capability of reducing 5-((4S)-2-oxo-4-phenyl(1,3-oxazolidin-3-yl))-1-(4-fluorophenyl)pentane-1,5-dione to (4S)-3-[(5S)-5-(4-fluorophenyl)-5-hydroxypentanoyl]-4-phenyl-1,3-oxazolidin-2-one. Also provided are polynucleotides encoding the engineered ketoreductase enzymes, host cells capable of expressing the engineered ketoreductase enzymes, and methods of using the engineered ketoreductase enzymes to synthesize the intermediate (4S)-3-[(5S)-5-(4-fluorophenyl)-5-hydroxypentanoyl]-4-phenyl-1,3-oxazolidin-2-one in a process for making Ezetimibe.

Abstract: The invention relates to a Piroplasmid protein or an immunogenic fragment of said protein, and to a nucleic acid encoding said Piroplasmid protein or said immunogenic fragment. Furthermore, the invention relates to cDNA fragments, recombinant DNA molecules and live recombinant carriers comprising said nucleic acid. Also the invention relates to host cells comprising said cDNA fragments, recombinant DNA molecules and live recombinant carriers. Finally, the invention relates to vaccines comprising a Piroplasmid protein or an immunogenic fragment of said protein, to methods for the preparation of such vaccines, to the use of such proteins or fragments for vaccine purposes, and to diagnostic tests.

Abstract: The invention relates to a Piroplasmid protein or an immunogenic fragment of the protein, and to a nucleic acid encoding the Piroplasmid protein or the immunogenic fragment. Furthermore, the invention relates to cDNA fragments, recombinant DNA molecules and live recombinant carriers comprising the nucleic acid. Also the invention relates to host cells comprising the cDNA fragments, recombinant DNA molecules and live recombinant carriers. Finally, the invention relates to vaccines comprising a Piroplasmid protein or an immunogenic fragment of the protein, to methods for the preparation of such vaccines, to the use of such proteins or fragments for vaccine purposes, and to diagnostic tests.

Abstract: The invention relates to a Piroplasmid protein or an immunogenic fragment of said protein, and to a nucleic acid encoding said Piroplasmid protein or said immunogenic fragment. Furthermore, the invention relates to cDNA fragments, recombinant DNA molecules and live recombinant carriers comprising said nucleic acid. Also the invention relates to host cells comprising said cDNA fragments, recombinant DNA molecules and live recombinant carriers. Finally, the invention relates to vaccines comprising a Piroplasmid protein or an immunogenic fragment of said protein, to methods for the preparation of such vaccines, to the use of such proteins or fragments for vaccine purposes, and to diagnostic tests.